Erdafitinib Granted Breakthrough Therapy Designation by FDA for Urothelial Carcinoma
Based on the phase II study BLC2001, erdafitinib has been granted a breakthrough therapy designation by the FDA for the treatment of metastatic urothelial carcinoma, according to Janssen, the manufa...